--- title: "10x Genomics Inc. Risk Monitoring" description: "10x Genomics Inc. financial risk indicators from its SEC filings (leverage, liquidity, interest coverage, debt load) compared with peers, with filings linked." canonical: https://www.getswoopr.com/stocks/companies/10x-genomics-inc/risks-monitoring/ source: "Swoopr Investment: https://www.getswoopr.com" --- # 10x Genomics Inc. Risks & Monitoring Guide ## Direct Answer > 10x Genomics Inc.'s fiscal 2025 filings show a net loss of $44 million. These figures measure financial risk only; the business risks 10x Genomics Inc. itself considers material are listed under Item 1A, Risk Factors, of its Form 10-K, most recently filed February 13, 2026. ## What Do 10x Genomics Inc.'s Financial Risk Indicators Show? | Indicator (fiscal 2025) | 10x Genomics Inc. | Peer median (same SIC code) | What it measures | | --- | --- | --- | --- | | Liabilities to assets | 24% | 40% | How much of the balance sheet is funded by obligations rather than equity. | | Current ratio | 4.5x | 2.2x | Short-term assets per dollar of obligations due within a year. | | Interest coverage | n/a | 6.3x | Operating income per dollar of interest expense. | | Long-term debt to operating cash flow | n/a | 2.2x | Years of operating cash flow it would take to repay long-term debt. | | Net debt | Not reported | n/a | Long-term debt minus cash; negative means more cash than long-term debt. | The peer median uses 19 other companies in Swoopr's S&P 500 Equal Weight set that share the same SEC SIC code. A reading worse than the peer median is a prompt to read the filing, not a conclusion. ![Bar chart of 10x Genomics Inc. balance sheet at the end of fiscal 2025: total assets $1.0 billion, total liabilities $245 million, shareholders' equity $796 million, cash and equivalents $474 million.](https://www.getswoopr.com/images/charts/10x-genomics-inc-risks-balance-sheet.webp) *10x Genomics Inc. balance sheet items at the end of fiscal 2025, from the figures in the table above. Long-term debt is highlighted. Select the chart to open it full size.* ## Where Are 10x Genomics Inc.'s Official Risk Factors? The risks 10x Genomics Inc. considers material are disclosed in Item 1A of its Form 10-K, most recently [filed February 13, 2026](https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm). Read them with three questions in mind: which risks are specific to this company rather than generic, which have changed since the prior year's filing, and which connect to the figures above (a refinancing risk matters more when interest coverage is thin). ## Where These Numbers Come From Every figure on this page is a value 10x Genomics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001628280-26-007822 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### Is 10x Genomics Inc. highly leveraged? At the end of fiscal 2025, 10x Genomics Inc.'s total liabilities were 24% of total assets, against a peer median of 40%. Leverage that is normal for one industry (banks, utilities) can be high for another. ### Where are 10x Genomics Inc.'s official risk factors? In Item 1A, Risk Factors, of its annual report on Form 10-K, most recently filed with the SEC on February 13, 2026. The company lists the risks it considers material there; the measures on this page only quantify the financial side. ### Can 10x Genomics Inc. pay its interest? 10x Genomics Inc. did not report interest expense under the standard tags for fiscal 2025, so interest coverage is not computed here; its income statement and debt footnote show the details. ## References - [SEC EDGAR: 10x Genomics, Inc. Form 10-K filed February 13, 2026](https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm) - [SEC EDGAR: 10x Genomics, Inc. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1770787&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [10x Genomics Inc. company dossier](https://www.getswoopr.com/stocks/companies/10x-genomics-inc/) - [10x Genomics Inc. financial metrics](https://www.getswoopr.com/stocks/companies/10x-genomics-inc/financial-metrics/) - [10x Genomics Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/10x-genomics-inc/risks-monitoring/) - [10x Genomics Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/10x-genomics-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).